drugset

Drugs / Autologous Anti-CD19/CD20/CD22 CAR T-cells

Follow last change Jan 2026 re-read 3 minutes ago

Autologous Anti-CD19/CD20/CD22 CAR T-cells

Developed for: B-cell chronic lymphocytic leukemia · blast phase chronic myelogenous leukemia, BCR-ABL1 positive · lymphoblastic lymphoma · Richter transformation
Investigated by: Ohio State University Comprehensive Cancer Center

Trials 1

today NCT07166419 · Ph 1

2027

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 1	NCT07166419	Jan → Dec 2026	B-cell chronic lymphocytic leukemia, Richter transformation, blast phase chronic myelogenous leukemia, BCR-ABL1 positive, lymphoblastic lymphoma	Ohio State University Comprehensive Cancer Center	Suspended	No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

Field	Value	Cited text
Known as	Autologous Anti-CD19/CD20/CD22 CAR T-cells	ClinicalTrials.gov intervention name — accepted as the source's own label NCT07166419 ↗
Modality	Cell therapy	“anti-CD19/20/22 chimeric antigen receptor (CAR) T cells” NCT07166419 ↗
Route	Intravenous	“Given IV” NCT07166419 ↗